News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Galderma Laboratories Announces Positive Results From The “Commplete” Regimen Study Including Epiduo Gel In The Management Of Acne In Adolescent Student Athletes 5/24/2016
After Initial Miss, GlaxoSmithKline (GSK)'s Pioneering Lung Study Shows Positive Results 5/24/2016
Relypsa (RLYP) Release: Data From New Analyses Of Studies With Veltassa Presented At 53rd European Renal Association Congress 5/23/2016
Sunovion Pharmaceuticals Inc.Announces Publication Of Data Evaluating The Long-Term Safety And Tolerability Of Latuda (Lurasidone Hcl) In The Treatment Of Bipolar Depression 5/23/2016
STELVIO Trial Shows Sustained Benefits For Emphysema Patients One Year After Treatment With Pulmonx, Inc.'s Zephyr Endobronchial Valves 5/19/2016
First Patient Enrolled In Mallinckrodt (MNK) Phase 4 Trial Of H.P. Acthar Gel For Rare Cause Of Nephrotic Syndrome 5/18/2016
BioPharmX Presents At American Congress Of Obstetricians And Gynecologists (ACOG) Suggesting Molecular Iodine May Be Effective, Non-Hormonal Treatment For FBC 5/16/2016
Sunovion Pharmaceuticals Inc. Announces Health Outcomes Data On Exacerbation-Related Hospitalizations That Support The Use Of Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society Conference 5/16/2016
Egalet Human Abuse Potential Data At American Pain Society Annual Meeting Demonstrates Significantly Lower Intranasal Abuse Potential Of ARYMO ER Compared To MS Contin 5/12/2016
Alimera Sciences (ALIM)' ILUVIEN Data Presented At 2016 Association for Research in Vision & Ophthalmology 5/6/2016
Starpharma Release: VivaGel Active Against Zika Virus 5/5/2016
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
Eli Lilly (LLY) Release: Jardiance (Empagliflozin) To Be Studied For The Treatment Of People With Chronic Heart Failure 4/19/2016
Bristol-Myers Squibb (BMY) Release: First Presentation Of Overall Survival Data For Opdivo (Nivolumab) Shows Significant Survival Benefit At One-Year Versus Investigator’s Choice In Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck 4/19/2016
Immune Pharma Release: New Biomarker Data To Be Presented At AACR Helps Predict Overall Survival In Patients With Acute Myeloid Leukemia (AML) Treated With Ceplene And Low-Dose IL-2 Immunotherapy, Including Those Over 60 Years Of Age 4/19/2016
Janssen Release: New Data From U.S. Post-Approval Study Assess Ischemic Stroke And Intracranial Hemorrhage Rates In People With Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban With Warfarin And Apixaban With Warfarin 4/18/2016
New Data Suggesting Positive Effects Of Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) On Brain Volume Loss And Retinal Nerve Fibers To Be Presented At American Academy of Neurology 4/18/2016
Janssen Release: Real-World Study Further Confirms Safety Profile Of XARELTO In Nearly 45,000 People With Non-Valvular Atrial Fibrillation (NVAF), Including Those With Concomitant Diabetes 4/4/2016
Novo Nordisk A/S (NVO) Release: Victoza (liraglutide [rDNA origin] injection) Provided Superior Hba1c Reductions In Adults With Type 2 Diabetes Compared To Continued Sitagliptin Treatment 4/4/2016
Health Canada Approves BioPharmX Study Of Violet Iodine 4/4/2016
Cardiome Pharma Corp. (COM.TO) Announces Publication Of Independent Study Comparing BRINAVESS To Ibutilide In Patients With Recent-Onset Atrial Fibrillation 3/31/2016
Specialised Therapeutics Asia Release: Novel Multiple Myeloma Drug Aplidin Shows Positive Results In Pivotal Phase 3 Study 3/31/2016
AstraZeneca PLC (AZN) Release: BRILINTA Preferred Over Clopidogrel In Updated American College of Cardiology And AHA Guideline In Acute Coronary Syndrome 3/31/2016
Janssen Research & Development Release: First Phase 3 Trial Of Daratumumab In Combination With Standard Therapy In Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint In Planned Interim Analysis 3/30/2016
Boehringer Ingelheim Launches RE-COVERY DVT/PE: Global Observational Study On Management Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) With Pradaxa (Dabigatran Etexilate) 3/23/2016
AstraZeneca PLC (AZN)'s Brilinta Fails to Hit Main Goal of Stroke Study 3/23/2016
BioPharmX Initiates Post-Market Phase IV Study For Fibrocystic Breast Condition (FBC) And Cyclic Mastalgia 3/22/2016
SoCal's Aerie (AERI) Reports Positive Safety Data for Rhopressa 3/18/2016
Gilead (GILD) Shuts Down Six Zydelig Trials Following European Medicines Agency Review 3/17/2016
Viralytics Ltd (VLA.AX) Release: Positive CAVATAK Clinical Data Presented At 2016 European Association Of Urology Congress 3/15/2016
Janssen Pharmaceuticals, Inc. Release: First Real-World Evidence Comparing An SGLT2 Inhibitor With DPP-4 Inhibitors Shows Adults With Type 2 Diabetes Achieve Greater Blood Glucose Control With INVOKANA (canagliflozin) 3/14/2016
Boehringer Ingelheim Release: New Analyses: Adding SPIRIVA RESPIMAT Effective For Uncontrolled Asthma - Regardless Of Allergy Subtype 3/8/2016
New Novartis AG (NVS) Data Show Cosentyx Demonstrated Sustained Superiority In Skin Clearance (PASI 90) Versus Stelara At Week 52 3/7/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Long-Term Safety Data Presented At American Academy of Dermatology Congress 3/7/2016
AstraZeneca PLC (AZN), Novo Nordisk A/S (NVO) Investors Pin Hopes on Data from Two Closely-Watched Trials 3/2/2016
AEterna Zentaris (AEZS) Reports On Zoptrex Development Progress In China 3/1/2016
Arizona Pharmaceuticals Release: New Analysis Re-Affirms IR-Niacin As Evidence-Based Therapy For Dyslipidemia 3/1/2016
Female Libido Drug that Valeant (VRX) Bought for $1 Billion Gets Mixed Reviews 3/1/2016
Boehringer Ingelheim Release: New Analysis Confirms OFEV® (Nintedanib) Slows Disease Progression In IPF And Reduces Risk Of Acute Exacerbations 2/25/2016
ChromaDex, Inc. Announces Commencement Of An Obesity-Related Clinical Study Of NIAGEN In Collaboration With The University of Copenhagen And Aarhus University 2/22/2016
Amgen (AMGN)'s Aranesp Meets Primary Goal in Late Stage Trial 2/16/2016
Cumberland Pharmaceuticals (CPIX) Release: Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics 2/10/2016
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range Of Measures 2/9/2016
EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase III Clinical Study For BOW015 (Infliximab Biosimilar) 2/9/2016
Valeant (VRX) Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a Placebo 2/3/2016
Journal of Clinical Oncology Publishes Results From The STRIVE Trial Of enzalutamide Compared To bicalutamide In Castration-Resistant Prostate Cancer 1/27/2016
First U.S. Patient Treated Following FDA Approval Of Cook Medical’s Zenith Alpha Thoracic Endovascular Graft 1/26/2016
Omeros Corporation (OMER) Release: Disclosure Of Omidria Post-Launch Study Findings To Occur At Hawaiian Eye And Retina Conference 1/18/2016
Hi-Tech Pharmaceuticals Announces OTC Nationwide Launch Of New Diet Pill -- Ionamin -- Backed By Clinical Study 1/12/2016
Regeneron (REGN) Investors Get Jitters From False Praluent Data 1/8/2016
ImaginAb, Inc.'s PSMA Imaging Agent Detects More Lesions Compared To Standard Imaging Methods For Detection Of Prostate Cancer In Phase I/Ila Study 1/6/2016
Teva (TEVA), Active Biotech (BTPC) Stop Higher Doses of Laquinimod in Two Multiple Sclerosis Trials 1/4/2016
Primary Endpoint Met in Baxalta (BXLT) and Momenta (MNTA)'s Biosimilar Study of Humira 12/22/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-166 (Ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis 12/16/2015
Collegium (COLL) Announces Publication Of Nasal Human Abuse Potential Study In American Academy Of Pain Medicine 12/16/2015
Zydelig Study May Finally Transform Gilead (GILD) into a Cancer Powerhouse 12/11/2015
Defective Device Forces Regulators to Take a Hard Look at Bayer (BAY)'s Xarelto Trial 12/9/2015
Merck & Co. (MRK) Release: Findings Across A Range Of Hematological Cancers Add To The Growing Breadth Of KEYTRUDA (Pembrolizumab) Data 12/8/2015
Janssen Pharmaceutical Release: Real-World Data Confirms Safety And Efficacy Profile Of XARELTO, With Shorter Hospital Stays, For The Treatment Of Deep Vein Thrombosis 12/8/2015
ContraVir Reports Key CMX157 Data At HEP DART 2015 Demonstrating Enhanced In Vitro Safety Profile Compared To Viread 12/8/2015
Merck & Co. (MRK) Release: Findings Across A Range Of Hematological Cancers Add To The Growing Breadth Of KEYTRUDA (Pembrolizumab) Data 12/8/2015
SteadyMed (STDY) Demonstrates Potential For Reduced Infusion Site Sensitivity Associated With Trevyent Compared To Remodulin 12/7/2015
AbbVie (ABBV) Release: IMBRUVICA (Ibrutinib) Phase 3 RAY Data Show Significant Reductions In Disease Progression Versus Temsirolimus In Relapsed/Refractory Mantle Cell Lymphoma Patients 12/7/2015
Researchers Find Additional Benefits of Novartis AG (NVS)'s Heart Failure Drug Entresto 12/3/2015
H. Lundbeck A/S (LUN.CO) Release: Largest Prospective Study Evaluating The Effect Of Vigabatrin On Vision 11/25/2015
BioMarin (BMRN) Stocks Drop After FDA Panel is Critical of DMD Treatment Drisapersen 11/23/2015
VBL Therapeutics (VBLX) Announces Significant Improvement Of 12 Month Overall Survival With VB-111 Compared To Pooled Data From Four Avastin Studies At The Annual Meeting Of The Society For Neuro-Oncology 11/19/2015
Astellas (ALPMY) Announces Results From The First Head To Head Study Comparing QUTENZATM (Capsaicin 8% Patch) With Current Standard Of Care In Patients With Peripheral Neuropathic Pain 11/19/2015
Merck & Co. (MRK) Provides Update On REVEAL Outcomes Study 11/13/2015
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From A Phase IV Study To Assess And Compare The Effects Of Silenor 6 Mg And Zolpidem 10 Mg On Balance, Cognitive Performance, And Arousability 11/13/2015
AstraZeneca PLC (AZN) Release: PEGASUS-TIMI 54 Sub-Analysis Outlines Long-Term Tolerability Data For BRILINTA 11/10/2015
Boehringer Ingelheim Release: New Jardiance (Empagliflozin) Data Show Improved CV Outcomes Regardless Of Heart Failure Status At Baseline 11/9/2015
ArmaGen Technologies, Inc. Receives Rare Pediatric Disease Designation From FDA For AGT-181 For The Potential Treatment Of Hurler Syndrome (Mucopolysaccharidosis Type I) 11/5/2015
Pfizer (PFE) Release: New Data Continue To Characterize The Safety And Efficacy Of XELJANZ (Tofacitinib Citrate) In The Treatment Of Rheumatoid Arthritis 11/2/2015
FDA Bestows Merck & Co. (MRK)'s Keytruda with Breakthrough Status to Treat Advanced Colorectal Cancer 11/2/2015
Boehringer Ingelheim Release" CHEST: New Sub-Analyses Show Improvement In COPD Patient Outcomes With Spiolto Respimat 10/28/2015
Momenta (MNTA) Announces Publication Of Two Glatopa (Glatiramer Acetate Injection) Manuscripts 10/26/2015
Mundipharma AG: New Study Provides Insights Into Potential Treatment Of Severe Pain In Parkinson’s Disease With Prolonged-Release Oxycodone/Naloxone 10/20/2015
Novartis AG (NVS) Cancer Drug May Help Parkinson's Patients 10/19/2015
Sunovion Pharmaceuticals Inc. To Present Health Outcomes Data Supporting Brovana® (Arformoterol Tartrate) Inhalation Solution In Patients With COPD At The 2015 American College of Chest Physicians Annual Meeting 10/19/2015
EMD Serono Announces Publication Of PRISMS-15 Yr Follow-Up Study In Patients Using Rebif (interferon beta-1a), Focused On Factors Influencing Outcomes In RRMS 10/13/2015
Abbott (ABT)'s Absorb Passes First Large Test 10/13/2015
Indian Drugmakers Like Cipla (CIPLA) and BDR Pharma Work on Hepatitis C Cocktails Impossible in the U.S. 10/12/2015
Amgen (AMGN) Release: New Data Show Greater Bone Mineral Density Gains With Prolia (Denosumab) Compared With Zoledronic Acid 10/12/2015
Gedeon Richter (RIG2.F) Release: Full Results Of PEARL IV Study Presented At The European Society Of Gynaecological Endoscopy (ESGE) Congress Confirms The Efficacy Of Ulipristal Acetate 5 Mg For The Long Term Management Of Uterine Fibroids 10/9/2015
Sanofi Genzyme (SNY) Touts Long-Term Data for Multiple Sclerosis Drug Lemtrada 10/8/2015
Marathon Pharmaceuticals, LLC Receives Rare Pediatric Disease Designation From FDA For Deflazacort As A Potential Treatment Of Duchenne Muscular Dystrophy 10/7/2015
AstraZeneca PLC (AZN) Release: SYMBICORT Real-World Study Results Published In The International Journal Of COPD 9/30/2015
Boehringer Ingelheim Release: New Data Demonstrate Sustained Long-Term Efficacy Of OFEV* On Slowing Disease Progression And Safety In Patients With IPF 9/29/2015
Patients With Aggressive Form Of Melanoma Lived For More Than Two Years On Average When Taking Novartis Pharmaceutical Corporation (NVS) Therapies Tafinlar + Mekinist 9/28/2015
Boehringer Ingelheim Release: New Head-to-Head STIOLTO RESPIMAT Data Presented At ERS Annual Congress 9/28/2015
Alimera Sciences (ALIM) Announces ILUVIEN Study Results Presented At 15th Euretina Congress 9/24/2015
Hemispherx (HEB) Reports Article By Senior Authors From Italian Ministry Of Health And Related Agencies Suggesting Broad Applicability Of Ampligen To Multiple Sclerosis 9/23/2015
More Than 50 Presentations Of New Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured At ECTRIMS 9/23/2015
ViiV Healthcare Release: New Phase IIIb/IV Data Show Switching To Once-Daily Triumeq Maintains HIV Viral Suppression 9/23/2015
MerLion Pharmaceuticals GmbH’s Finafloxacin Shown To Be More Efficacious Than Ciprofloxacin In The Treatment Of Complicated Urinary Tract Infections 9/21/2015
ERS 2015: Landmark Year For Boehringer Ingelheim’s Respiratory Portfolio - New Data For COPD, IPF And Asthma Treatments 9/21/2015
AmpliPhi Biosciences Corporation (APHB) Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model 9/21/2015
New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company (MDCO) 9/21/2015
Eli Lilly (LLY) Diabetes Drug Slashes Deaths in Patients With Heart Risk 9/18/2015
Merck & Co. (MRK)'s Once-Weekly Diabetes Drug Works Same as Januvia; Drugmaker Plans to File Drug by End of 2015 9/17/2015
Novo Nordisk A/S (NVO)’s Victoza Beats Sanofi (SNY)’s Lixisenatide in Head-to-Head Study, Company Says 9/17/2015
Amicus (FOLD) Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA 9/15/2015
GlaxoSmithKline (GSK), Theravance (THRX)'s Breo Fails to Extend Lives in Ambitious Study 9/10/2015
Bristol-Myers Squibb (BMY) And Pfizer (PFE) Enroll First Patient In Phase 4 AUGUSTUS Trial To Evaluate Safety Of Eliquis (Apixaban) In Nonvalvular Atrial Fibrillation Patients With A Recent Acute Coronary Syndrome Or Undergoing Percutaneous Coronary Intervention 9/9/2015
GlaxoSmithKline (GSK) And Theravance (THRX) Announce Results From The SUMMIT COPD CV Survival Study 9/9/2015
DelMar Pharmaceuticals Presents Clinical Protocol For Advancement Of VAL-083 Into Phase IV Studies As A Treatment For Non-Small Cell Lung Cancer 9/8/2015
Collegium (COLL) To Present Highlights From Xtampza ER (Oxycodone Extended-Release Capsules) Clinical Development Program At Painweek 9/4/2015
Regeneron (REGN) And Sanofi (SNY) Announce New Positive Praluent (alirocumab) Phase 3 Data Presented At ESC Congress 2015 9/1/2015
Merck & Co. (MRK) Release: New Analyses From The IMPROVE-IT Study With VYTORIN (Ezetimibe And Simvastatin) 9/1/2015
Boehringer Ingelheim Release: New Analysis Shows Idarucizumab Enables Rapid Initiation Of Emergency Surgery In Dabigatran-Treated Patients 9/1/2015
Eli Lilly (LLY)'s Diabetes Drug Jardiance May Put the Brakes on Heart Disease 8/28/2015
Merck & Co. (MRK) Release: New Analyses From The IMPROVE-IT Outcomes Study Of VYTORIN (Ezetimibe And Simvastatin) And The TECOS Cardiovascular Safety Trial Of JANUVIA (Sitagliptin) Will Be Presented At The European Society of Cardiology Congress 8/20/2015
Intarcia Diabetes Implant Beats Merck & Co. (MRK)'s $6 Billion Drug in Head-to-Head Study 8/20/2015
Novartis AG (NVS) Reports Third Case of PML in Relapsing MS Patient Treated with Gilenya 8/19/2015
Veloxis Pharmaceuticals A/S (VELO) Envarsus XR Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis 8/17/2015
GlaxoSmithKline (GSK) Hopes Huge Trial Will Revive Flagging Lung Drug Biz 8/14/2015
Roche (RHHBY)'s Avastin Not Linked to Higher Risk of Blindness 8/14/2015
Results From First Human Clinical Study Demonstrate ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Effectively Increases The Co-Enzyme NAD+ And Is Safe 8/12/2015
Oasmia's Paclical Does Well in Head to Head Study with Celgene (CELG)'s Abraxane 8/4/2015
Pfizer (PFE) Pulls Plug on OTC Lipitor After Trial Failure 7/30/2015
Takeda (TKPYY) Announces Completion Of The Pioglitazone Post-Marketing Commitment And Submission Of Results To The European Medicines Agency, The European Medicines Agency And The PMDA 7/30/2015
AVANIR Pharmaceuticals (AVNR) Announces New Findings From Dementia/Alzheimer's Disease Cohort Of PRISM II Study At Alzheimer's Association International Conference 7/23/2015
Portola Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not 6/25/2015
Collegium (COLL) Announces Publication of "Comparing the Effect Of Tampering On The Oral Pharmacokinetic Profiles Of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," In Pain Medicine 6/25/2015
Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence At 60 Mg Dose 6/25/2015
Protein Sciences Corporation Release: New Clinical Study of Flublok Influenza Vaccine Shows That Groundbreaking Flublok Is More Effective Than The Traditional Flu Shot 6/25/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Differentiated Pharmacokinetic Profile Compared To Twice-Daily Prograf Or Once-Daily Astagraf XL In Stable Kidney Transplant Patients 6/24/2015
MediciNova, Inc. Announces New Article Published On MN-166 (Ibudilast) In Addiction Biology 6/16/2015
Kyowa Hakko USA, Inc. Release: Combination Setria Glutathione And L-Citrulline Supplementation Proven To Increase Post-Exercise Benefits 6/15/2015
Vernalis PLC (VNLPY.PK) Announces CCP-07 Starts 12 Month Stability Testing 6/11/2015
Zealand Pharma  (ZEAL.CO) Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial 6/9/2015
Zealand Pharma  (ZEAL.CO) Informs Of Updates Given By Sanofi (SAN.PA) On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes 6/9/2015
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SAN.PA) Has Informed Of Results From Getgoal Duo-2, Showing Advantages Of Lyxumia Versus Rapid-Acting Insulin As Add-On To Lantus For The Treatment Of Type 2 Diabete 6/8/2015
New Data Show Superiority of Eli Lilly (LLY)'s Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes 6/8/2015
Sanofi (SAN.PA) Announces Study Program Evaluating Toujeo In A Real-Life Setting 6/4/2015
Matinas BioPharma's MAT9001 Meets Primary And Secondary Endpoints In First Human Trial Versus Vascepa 6/1/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015
FDA Grants Fast Track Designation For IntelliPharmaCeutics Rexista Oxycodone XR Incorporating PODRAS Technology 5/26/2015
Astellas Pharma US Release: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 5/18/2015
AbbVie (ABBV) Receives Orphan Drug Designation For HUMIRA (Adalimumab) From The FDA For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa (HS) 5/15/2015
Orexigen (OREX) Provides Statement On Termination Of The Light Study And Updates On Contrave Collaboration With Takeda Pharmaceuticals 5/13/2015
Boehringer Ingelheim Release: First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/13/2015
Orexigen (OREX) Aborts Required Study For Diet Drug Contrave 5/13/2015
Heart-Stopping Morning Leads to Vertex (VRTX) Rise As FDA News Sees Positives 5/11/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation By The Hemispherx Biopharma (HEB) For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 5/11/2015
Bristol-Myers Squibb (BMY) Release: Long-Term, 7-Year Study Of Nulojix (Belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction Of Death Or Graft Loss Over Cyclosporine Regimen In Kidney Transplant 5/6/2015
Kowa Pharmaceuticals America Release: New Meta-Analysis On Pitavastatin Demonstrates No Adverse Effect Compared With Placebo Or Other Statins On New-Onset Diabetes In Non-Diabetic Patients At Risk For Cardiovascular Disease 5/4/2015
Bayer HealthCare (BAY) Release: Five-Year Follow-Up Study Further Supports Effectiveness And Safety Of The Essure Procedure As A Non-Surgical, Non-Hormonal Option For Permanent Contraception 5/1/2015
Actavis (ACT) And Medicines360 Announce Publication Of ACCESS IUS Efficacy And Safety Study Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception 4/29/2015
Gilead (GILD) Offers Free Drugs in Georgia in Hep C Eradication Experiment 4/24/2015
Teva (TEVA) Presents Data Comparing Early Treatment With COPAXONE 40 Mg/Ml To Delayed Start Treatment At 67th American Academy of Neurology Annual Meeting In Washington, D.C. 4/23/2015
Effect Of Genzyme (GENZ)’s Multiple Sclerosis Treatment Lemtrada (Alemtuzumab) On Slowing Brain Atrophy And MRI Lesion Activity Maintained Through Four Years 4/23/2015
Momenta Pharmaceuticals, Inc. (MNTA) Presents Key Glatopa (Glatiramer Acetate Injection) Data At American Academy of Neurology Annual Meeting 4/20/2015
Biogen (BIIB) Release: TECFIDERA (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy For Newly-Diagnosed MS Patients 4/20/2015
AstraZeneca PLC (AZN)'s Diabetes Drug Onglyza May Increase Risk of Heart Failure, FDA Panel Reports 4/13/2015
Roche (RHHBY) Scientists Testing to See if Arthritis Blockbuster Will Work for Diabetes 4/10/2015
Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/25/2015
Deaths Review of Eli Lilly (LLY)'s Antipsychotic Zyprexa Relprevv "Inconclusive" 3/25/2015
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion On Application For Orphan Designation By The European Medicines Agency Agency For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 3/24/2015
Hemispherx Biopharma (HEB) To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus 3/23/2015
Merz Aesthetics (Formerly Known as BioForm Medical, Inc.) Announces Primary Endpoint Met In Post-Market Clinical Study Of Xeomin (Incobotulinumtoxina) Vs. Botox® (Onabotulinumtoxina) For Glabellar Facial Lines 3/19/2015
Lundbeck Inc. (LUN.CO) Initiates Clinical Trial Evaluating Clobazam For Dravet Syndrome 3/17/2015
Boehringer Ingelheim Release: Many Atrial Fibrillation Patients At High Risk Of Stroke Fail To Receive Guideline-Recommended Oral Anticoagulant Treatment 3/16/2015
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015
Pfizer (PFE) Pain Med Lyrica Flunks Post Market Study in Adolescents 3/13/2015
Pfizer (PFE) Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia 3/13/2015
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Prurigo Nodularis 3/11/2015
Merck & Co. (MRK) Release: Two New Post-Hoc Analyses Of TRA 2°P TIMI 50 Study Showed ZONTIVITY (Vorapaxar) Added To Aspirin And/Or Clopidogrel Reduced Acute Limb Ischemia And Peripheral Revascularizations, Respectively, In Certain Patients With Peripheral Arterial Disease 3/5/2015
Merck & Co. (MRK) Release: New Data From IMPROVE-IT Study Of VYTORIN® (Ezetimibe/Simvastatin) And TRA 2ºp TIMI 50 Study Of ZONTIVITY® (Vorapaxar) To Be Presented At American College of Cardiology Scientific Sessions 2/25/2015
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/25/2015
Celltrion Healthcare: Data Show The World’s First European Medicines Agency-Approved Biosimilar Monoclonal Antibody Remsima Could Reduce Cost Of Treating Crohn’s Disease By Up To €336 Million Over Five Years 2/20/2015
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/20/2015
Novartis AG (NVS) May Already Have First True Anti-Aging Drug in Its Pipeline 2/19/2015
Regeneron (REGN) Release: NIH-Sponsored Comparative Effectiveness Trial In Diabetic Macular Edema Shows EYLEA (Aflibercept) Injection Demonstrated Significantly Greater Gains In Visual Acuity Than Both Bevacizumab And Ranibizumab 2/19/2015
Pfizer (PFE)'s Chantix Effective for Smokers 2/18/2015
Cumberland Pharmaceuticals (CPIX) Release: Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor® (ibuprofen) Injection 2/2/2015
New Study Vindicates Efficacy of Roche (RHHBY)'s Blockbuster Drug Tamiflu 2/2/2015
AstraZeneca PLC (AZN)'s Brilinta Boosted by Major Clinical Trial Success 1/14/2015
Ipsen (IPN.PA) To Present Further Data On Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (Lanreotide), At Gastrointestinal Cancers Symposium 1/13/2015
DBV Technologies Announces Publication In The Journal Of Allergy And Clinical Immunology Of Data Demonstrating That Epicutaneous Immunotherapy May Influence The Natural History Of Allergy 1/12/2015
Merck & Co. (MRK)'s Gardasil Not Linked To Multiple Sclerosis, JAMA Reveals 1/7/2015
Cerulean Pharma Inc. (CERU) Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models 1/6/2015
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Genentech (RHHBY) Provides Update On Phase 3 MARIANNE Study In People With Previously Untreated Advanced HER2-Positive Breast Cancer 12/19/2014
FDA Breakthrough Status For Genentech (RHHBY)'s Lucentis 12/17/2014
Pfizer (PFE)'s Top Selling Drug Doesn't Help Patients With Lower Back Pain 12/15/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
Hemispherx Biopharma (HEB) Announces Data Showing Inhibition Of Ebola By Ampligen® Enlarged By Howard University Research 12/9/2014
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014
Gilead Sciences, Inc. (GILD) Presents Follow-Up Data From Zydelig Registrational Studies In Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 12/8/2014
EXCLUSIVE: NHS Uses Ineffective IPF Therapy 12/5/2014
National Institute for Clinical Excellence (NICE) Requests More Info On Novartis AG (NVS)'s Xolair To Treat Chronic Hives 11/20/2014
Esperion Therapeutics, Inc. (ESPR) Climbs As CEO Lauds Merck & Co. (MRK)'s Zetia Data 11/19/2014
Merck & Co. (MRK)'s Vytorin Proves Effective; IMPROVE-IT Trial Achieves Primary Endpoint 11/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Longer-term Outcome Data From The Largest Prospective Trial Of Soliris® (Eculizumab) In aHUS Underscore The Effectiveness Of Ongoing Soliris Treatment 11/17/2014
Gilead Sciences, Inc. (GILD) Announces Harvoni Study Results In Chronic Hepatitis C Patients With Advanced Liver Disease And Those Who Failed Prior Treatment 11/11/2014
Confident Merck & Co. (MRK) Expects No Writedowns For Zetia, Vytorin Cholesterol Drugs 11/11/2014



//-->